

What is claimed is:

1. A method for treating chronic inflammation in a patient with inflammatory autoimmune disease comprising administering to the patient an amount of Bowman Birk Inhibitor effective to reduce, inhibit, suppress or prevent the chronic inflammation.
2. The method of claim 1, wherein the chronic inflammation is inflammation of neural tissue.
3. The method of claim 2, wherein the neuroinflammation affects the central nervous system or peripheral nervous system of the patient.
4. The method of claim 3, wherein demyelination of the nerve tissue of the patient is reduced, inhibited, suppressed or prevented.
5. The method of claim 1, wherein the patient is affected by the disease selected from the group consisting of Multiple Sclerosis, Guillain Barre Syndrome and rheumatoid arthritis.
6. The method of claim 1, wherein the patient is a mammal.
7. The method of claim 6, wherein the patient is a human.
8. The method of claim 1, wherein the Bowman Birk Inhibitor is administered orally.
9. The method of claim 1, wherein the Bowman Birk Inhibitor is administered as Bowman Birk Inhibitor Concentrate.
10. The method of claim 9, wherein the Bowman Birk Inhibitor is provided as an enriched concentrate extracted from a legume.
11. The method of claim 10, wherein the Bowman Birk Inhibitor is provided as an enriched concentrate extracted from soybeans.
12. The method of claim 1, wherein the Bowman Birk Inhibitor is administered to the patient with a carrier therefor.
13. The method of claim 1, wherein the Bowman Birk Inhibitor is administered with another therapeutic agent, drug, medicament, or therapy.
14. A method for treating inflammation in an animal model of an induced inflammatory disease comprising administering to the animal an amount of Bowman Birk Inhibitor effective to reduce, inhibit, suppress or prevent the chronic inflammation.
15. The method of claim 14, wherein the chronic inflammation is inflammation of neural tissue.

16. The method of claim 14, wherein the neuroinflammation affects the central nervous system or peripheral nervous system of the patient.
17. The method of claim 16, wherein demyelination of the nerve tissue of the patient is reduced, inhibited, suppressed or prevented.
18. The method of claim 14, wherein the disease is Experimental Autoimmune Encephalomyelitis or Experimental Autoimmune Neuritis.
19. The method of claim 18, wherein the Bowman Birk Inhibitor is administered orally as Bowman Birk Inhibitor Concentrate.